Variant Gene Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Many melanomas harbor a mutation in this pathway, BRAF(V600E), which constitutively activates MAPK signaling and expression of downstream target genes that facilitate tumor progression. 25989506

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer. 26477313

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Beyond development, we can look into the effectiveness of already approved targeted therapies (eg, anti-BRAF(V600E) selective inhibitors, tyrosine kinase inhibitors, histone deacetylase inhibitors, inhibitors of DNA methylation, etc) to potentially test in ATC after learning the molecular mechanisms that aid in tumor progression. 25347569

2015

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Therefore, these data indicate that PRDX1 and PRDX6 expression not only may play a key role in papillary thyroid carcinogenesis via a BRAF V600E-dependent mechanism, but their determination could be considered as potential tumor marker for indicating tumor progression in PTCs, independently of BRAF status. 24316730

2014

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. 23825589

2014

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. 23533235

2013

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Oncogenic B-RAF V600E mutation is found in 50% of melanomas and drives MEK/ERK pathway and cancer progression. 22730329

2012

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Correspondingly, in established murine BRAF(V600E)-driven nevi, acute shRNA-mediated depletion of PTEN prompted tumor progression. 22549727

2012

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. 21447745

2011

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Using gene set enrichment analysis and in vitro and in vivo functional studies, we identified and validated a B-Raf(V600E) gene set signature associated with tumor progression in PTCs. 20498063

2010

dbSNP: rs351855
rs351855
0.020 GeneticVariation BEFREE Thus, our findings elucidate the molecular mechanism behind the genetic association of rs351855 with accelerated cancer progression and suggest that germline variants of cell-surface molecules that recruit STAT3 to the inner cell membrane are a significant risk for cancer prognosis and disease progression. 26675719

2016

dbSNP: rs121913529
rs121913529
0.020 GeneticVariation BEFREE To determine which KRAS effectors were responsible for tumor progression, we created four effector domain mutants (S35, G37, E38 and C40) in G12V-activated KRAS and expressed these alone or with BrafV600E in mouse lungs... 24489653

2014

dbSNP: rs759728549
rs759728549
0.020 GeneticVariation BEFREE We crossed IL-6(-/-) mice with Kras(G12D) mutant mice, which develop lung tumors after activation of mutant Kras(G12D), to investigate whether IL-6 inhibition contributes to tumor progression and survival time in vivo. 24260500

2014

dbSNP: rs752021744
rs752021744
0.020 GeneticVariation BEFREE Additionally, we tested efficacy of PD-0325901 in Kras(G12D-LSL) conditional GEMMs (genetically engineered mouse models) which are a valuable tool in translational research to study tumor progression. 22684718

2012

dbSNP: rs759728549
rs759728549
0.020 GeneticVariation BEFREE The concomitant expression of oncogenic Kras(G12D) and mutant p53 (Trp53(R172H)) in the murine pancreas results in metastatic PDA that recapitulates the cognate features of human pancreatic cancer providing an excellent animal model to identify genes required for tumor progression. 22158044

2012

dbSNP: rs121913529
rs121913529
0.020 GeneticVariation BEFREE The transformed phenotype of IOE(CMYC) cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOE(CMYC) cells had undergone morphological and phenotypic changes characteristic of neoplastic progression. 21859834

2011

dbSNP: rs752021744
rs752021744
0.020 GeneticVariation BEFREE We hypothesized that tumor progression was because of concomitant activation of the mitogen-activated protein kinase pathway downstream of Kras(G12D) expression promoting cell survival and that the therapeutic effect of PF-04691502 would be enhanced by combinatory inhibition of MEK using PD-0325901. 21632463

2011

dbSNP: rs758272654
rs758272654
0.020 GeneticVariation BEFREE The present study provides strong evidence to suggest that the GNAS1 T393C allele carrier status influences tumor progression and survival in gastric cancer with higher tumor stages and a worse outcome for C allele carriers. 20027678

2010

dbSNP: rs758272654
rs758272654
0.020 GeneticVariation BEFREE Kaplan-Meier curves for tumor progression, development of metastasis, and tumor-related death showed a significant association of the T393C polymorphism with outcome (5-year cancer-specific survival rates: TT, 91%; TC, 81%; CC, 69%; P = 0.015). 16467086

2006

dbSNP: rs351855
rs351855
0.020 GeneticVariation BEFREE Three other nonparametric linear rank-tests particularly suitable for investigating possible relations between G388R mutation and early cancer progression were also used. 14710228

2004

dbSNP: rs121434569
rs121434569
0.010 GeneticVariation BEFREE Detection of T790M with plasma DNA was correlated with EGFR mutation type, exon 19 deletions and tumor progression. 26577492

2016

dbSNP: rs11568818
rs11568818
0.010 GeneticVariation BEFREE The -181A→G (rs11568818) polymorphism in the MMP7 promoter modulates gene expression and possibly affects cancer progression. 25847246

2015

dbSNP: rs4444235
rs4444235
0.010 GeneticVariation BEFREE LOH analysis suggested that the three CRC risk variants, rs12657484, rs3802842, and rs4444235, exhibited somatic allele-specific imbalance and might be critical during neoplastic progression. 24968322

2015

dbSNP: rs104893626
rs104893626
0.010 GeneticVariation BEFREE C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. 24711662

2014

dbSNP: rs11549465
rs11549465
0.010 GeneticVariation BEFREE Hypoxia-inducible factor-1 (HIF-1) influences cancer progression and metastasis through various mechanisms, and HIF-1α polymorphisms are reportedly associated with many cancers; however, the associations of HIF-1α P582S and A588T polymorphisms with the risk of digestive system cancer remain inconclusive. 24293391

2014